Compare Eli Lilly And Co (LLY) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs iShares MBS ETF — how do they compare? Eli Lilly And Co trades at $1,177.1 (market cap $1.04T), while iShares MBS ETF trades at $89.75 (market cap $35.41B). The key difference: Eli Lilly And Co is far larger — about 29.4× iShares MBS ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while iShares MBS ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and iShares MBS ETF for 96 Days on average.
| LLY | MBB | |
|---|---|---|
Market Cap | $1.04T | $35.41B |
Volume | 3,064,878 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $1.28K | $96.91 |
52-Week Low | $799.57 | $89.09 |
Typical Hold Time | 93 Days | 96 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.
MBB, the iShares MBS ETF, trades at $89.68, up 0.52% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock recently hit a new 52-week low of $91.02 on September 15, 2026, as short interest surged 98.3% in September, reflecting negative sentiment. Recent news highlights concerns over rising intermediate-term rates and inflation pressures impacting mortgage-backed securities.
The outlook remains cautious due to interest rate sensitivity and convexity risks in the mortgage market. While institutional buying by firms like Corient Private Wealth provides some support, the bearish technicals and macroeconomic headwinds suggest limited near-term upside. Key risks include further rate hikes and prepayment volatility in the MBS portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
